UPCC 34810 The Cardiovascular Effects of Sunitinib Therapy: Off-Target Changes in Cardiac Metabolism and Ventricular-Vascular Mechanics (CREST)

Tyrosine kinase inhibitors such as sunitinib are used in the treatment of renal cell carcinoma and have significant off-target effects with cardiac toxicity and resultant ventricular cardiac dysfunction being a major concern. However, the mechanisms of these effects in humans remains poorly defined, as are the clinical methods to risk stratify and identify patients who will ultimately suffer from cardiac dysfunction. The goal of this multi-center pilot study is to characterize the cardiovascular changes that occur with sunitinib through a detailed examination of: 1) sensitive echocardiographic measures of cardiac function; 2) comprehensive measures of arterial function and left ventricular afterload; 3) biomarkers reflective of the pathophysiologic alterations. Through this work, we will translate our basic science understanding of sunitinib cardiotoxicity to humans and identify early predictors of sunitinib cardiotoxicity.

You may be eligible for this study if you meet the following criteria:

• Conditions: Carcinoma, renal cell
• Age: 1 years - 99 years
• Gender: All